Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no random...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Immunol
Main Authors: Tomaszewska, Agnieszka, Jagasia, Madan, Beohou, Eric, van der Werf, Steffie, Blaise, Didier, Kanfer, Edward, Milpied, Noel, Reményi, Péter, Ciceri, Fabio, Bourhis, Jean H., Chevallier, Patrice, Solano, Carlos, Socié, Gerard, Bruno, Benedetto, Rambaldi, Alessandro, Castagna, Luca, Kröger, Nicolaus, Corradini, Paolo, Afanasyev, Boris, Ladetto, Marco, Niederwieser, Dietger, Scheid, Christof, Sengeloev, Henrik, Kroschinsky, Frank, Yakoub-Agha, Ibrahim, Schoemans, Helene, Koenecke, Christian, Penack, Olaf, Perić, Zinaida, Greinix, Hildegard, Duarte, Rafael F., Basak, Grzegorz W.
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2021
Fag:
Immunology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7884746/
https://ncbi.nlm.nih.gov/pubmed/33603743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.613954
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker